Regulations for in vivo radiopharmaceuticals used for diagnosis and monitoring--FDA. Proposed rule.
The Food and Drug Administration (FDA), in response to the requirements of the Food and Drug Administration Modernization Act of 1997 (FDAMA), is proposing to amend the drug and biologics regulations by adding provisions that would clarify the evaluation and approval of in vivo radiopharmaceuticals used in the diagnosis or monitoring of diseases. The proposed regulations would describe certain types of indications for which FDA may approve diagnostic radiopharmaceuticals. The proposed rule also would include criteria that the agency would use to evaluate the safety and effectiveness of a diagnostic radiopharmaceutical under the Federal Food, Drug, and Cosmetic Act (the act) and the Public Health Service Act (the PHS Act.
D017277:Drug Approval / Q000331:legislation & jurisprudence*; D006801:Humans; D019275:Radiopharmaceuticals / Q000592:standards* / Q000627:therapeutic use; D014481:United States; D014486:United States Food and Drug Administration